Pharmicell - Asset Resilience Ratio

Latest as of September 2025: 13.89%

Pharmicell (005690) has an Asset Resilience Ratio of 13.89% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩18.06 Billion

≈ $12.24 Million USD Cash + Short-term Investments

Total Assets

₩130.02 Billion

≈ $88.12 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Pharmicell's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Pharmicell to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Pharmicell's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pharmicell stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩18.06 Billion	13.89%
Total Liquid Assets	₩18.06 Billion	13.89%

Asset Resilience Insights

Moderate Liquidity: Pharmicell has 13.89% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Pharmicell Industry Peers by Asset Resilience Ratio

Compare Pharmicell's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Pharmicell (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Pharmicell.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.96%	₩2.94 Billion ≈ $1.99 Million	₩99.26 Billion ≈ $67.27 Million	+2.64pp
2023-12-31	0.33%	₩301.28 Million ≈ $204.17K	₩92.52 Billion ≈ $62.70 Million	-10.25pp
2022-12-31	10.58%	₩11.60 Billion ≈ $7.86 Million	₩109.65 Billion ≈ $74.31 Million	-0.05pp
2021-12-31	10.64%	₩10.03 Billion ≈ $6.80 Million	₩94.33 Billion ≈ $63.93 Million	+3.45pp
2020-12-31	7.19%	₩5.01 Billion ≈ $3.40 Million	₩69.74 Billion ≈ $47.26 Million	+3.84pp
2019-12-31	3.35%	₩2.12 Billion ≈ $1.44 Million	₩63.27 Billion ≈ $42.87 Million	-0.14pp
2018-12-31	3.49%	₩2.06 Billion ≈ $1.40 Million	₩59.12 Billion ≈ $40.06 Million	+2.96pp
2017-12-31	0.53%	₩337.72 Million ≈ $228.87K	₩63.75 Billion ≈ $43.20 Million	-6.51pp
2016-12-31	7.04%	₩7.17 Billion ≈ $4.86 Million	₩101.95 Billion ≈ $69.09 Million	+6.15pp
2013-12-31	0.89%	₩880.22 Million ≈ $596.51K	₩99.37 Billion ≈ $67.34 Million	-6.50pp
2012-12-31	7.39%	₩10.08 Billion ≈ $6.83 Million	₩136.43 Billion ≈ $92.45 Million	+1.95pp
2011-12-31	5.43%	₩5.50 Billion ≈ $3.73 Million	₩101.15 Billion ≈ $68.55 Million	+3.55pp
2010-12-31	1.89%	₩560.88 Million ≈ $380.10K	₩29.74 Billion ≈ $20.16 Million	--

pp = percentage points

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$418.84 Million

₩618.04 Billion KRW

Market Cap Rank

#13032 Global

#356 in Korea

Share Price

₩10300.00

Change (1 day)

+1.68%

52-Week Range

₩8760.00 - ₩20250.00

All Time High

₩25150.00